DHR · Q1 2026 Earnings

Cautious

Danaher Corporation

Reported April 21, 2026

30-second summary

30-second take: Q1 revenue of $6.0B (+3.5% YoY) hit consensus on the nose and non-GAAP EPS of $2.06 beat by 6.2%, but core sales growth of just 0.5% is the number that matters — well below the FY 3–6% guide and signaling that the entire year now depends on H2 acceleration. Management raised the FY26 EPS high end by $0.05 (to $8.35–$8.55), reaffirmed the 3–6% core revenue range, and quietly narrowed Cepheid respiratory from "approximately $1.7B" to "$1.6–$1.7B" — a hidden trim that nobody is calling out. Bioprocessing equipment orders +30% YoY (first positive print in nearly two years) is the one real green shoot; everything else is back-half-loaded promise.

Headline numbers

EPS

Q1 FY2026

$2.06

+6.2% vs est.

Revenue

Q1 FY2026

$6.00B

+3.5% YoY

0.0% vs est.

Gross margin

Q1 FY2026

60.3%

Free cash flow

Q1 FY2026

$1.08B

Operating margin

Q1 FY2026

22.6%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$6.00B	+3.5%	$6.84B	-12.3%
EPS	$2.06	—	$2.23	-7.6%
Gross margin	60.3%	—	58.0%	+233bps
Operating margin	22.6%	—	22.0%	+60bps
Free cash flow	$1.08B	—	$1.77B	-38.7%

Guidance

Company raised FY2026 EPS guidance to $8.35-$8.55 on strong Q1 beat, but Q1 core revenue growth of only 0.5% signals near-term deceleration; full-year core growth guidance of 3-6% implies material acceleration needed in H2.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS (non-GAAP)	Q1 FY2026	not explicitly guided	$2.06	EPS beat consensus estimate of $1.94 by 6.2%; company did not provide specific Q1 guidance	Beat
Core Revenue Growth	Q1 FY2026	low-single digit	0.5%	at the very low end of 'low-single digit' range; concerning deceleration from growth trajectory	Missed
Adjusted Operating Profit Margin (non-GAAP)	Q1 FY2026	—	26.5%	in-line with company expectations	Met

New guidance

Metric	Period	Guide	YoY
Core Revenue Growth	Q2 FY2026	low-single digit percent range year-over-year	low-single digit (approximately -2% to +3% YoY versus Q2 FY2025 baseline of $5.90B)
Adjusted Operating Profit Margin (non-GAAP)	Q2 FY2026	approximately 26.5%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS (non-GAAP)	FY2026	$8.35 to $8.50	$8.35 to $8.55	+$0.05 high-end raise (from $8.50 to $8.55); low-end reaffirmed	Raised
Cepheid Respiratory Revenue	FY2026	approximately $1.7 billion	approximately $1.6 to $1.7 billion	-$0.1B on low-end (from $1.7B point guidance to $1.6-1.7B range); implicit lowering of midpoint from $1.7B to $1.65B	Lowered

Reaffirmed unchanged this quarter: Core Revenue Growth (3% to 6% year-over-year)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026
Biotechnology Core Sales Growth	7.0%
Life Sciences Core Sales Growth	0.5%
Diagnostics Core Sales Growth	-4.0%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Core Sales Growth (non-GAAP)	0.5%
Adjusted Operating Profit Margin (non-GAAP)	26.5%
Operating Cash Flow	$1.322 billion
Free Cash Flow Margin	18.1%
Adjusted Diluted EPS Growth	9.5%

Management tone

Q3 FY25 anchor: modest 2026 recovery, equipment flat → Q1 FY26 anchor: equipment cycle starting, H2 acceleration required.

Equipment finally inflected — and management is willing to call it a cycle for the first time. Last quarter the FY26 build explicitly assumed equipment flat with no order conversion yet; in Q3 FY25, Schenkel said guidance "does not credit any of the improving customer confidence until it translates to order patterns." This quarter equipment orders printed +30% YoY, and the language stepped up to "we're in the early stages of a multi-year investment cycle." That is a structural reframe, not a sentiment nudge — moving bioprocessing equipment from cyclical headwind back to multi-year growth driver. The risk is that order conversion to revenue still takes 2–4 quarters, so the +30% doesn't show up in 2026 numbers in a material way.

Respiratory tone quietly went the other direction. Three quarters ago Cepheid respiratory was framed as a clean $1.7B endemic rate; this quarter it's "approximately $1.6 to $1.7 billion." Press release language called Q1 a "lighter than normal respiratory season." Management isn't saying the endemic rate is wrong, but they're widening the band downward without flagging it — exactly the kind of disclosure change that would draw a question on the call if there were one. With no transcript, this hidden cut is not being scrutinized.

Academic and China inflections are real but soft. Last quarter China was a $75–100M FY26 headwind; this quarter management said "volume growth in China was slightly better than our expectations, an encouraging indicator for future demand and growth" even as VBP pricing came in as expected. On academic, the shift is from "remained challenged" to "early signs of momentum building in our order book." Both are order-book signals, not revenue signals — useful for the H2 acceleration thesis but not yet showing in P&L.

AI was elevated to a strategic catalyst for the first time. Q3 FY25's narrative was cost-savings-and-modest-recovery; this quarter introduced AI as a multi-year growth thesis: "emerging opportunity in AI will further accelerate the pharma development and commercialization flywheel." No quantified targets, but the positioning is new and intended to anchor a higher-multiple narrative.

Recurring themes management leaned on this quarter:

Bioprocessing capacity expansion cycle beginningEnd-market headwinds moderating across portfolioChina biotech and life sciences acceleration offsetting diagnostics headwindsDBS-driven margin expansion and commercial execution driving resultsEarly signs of demand recovery in academic and biotech customer segmentsStrategic M&A (Massimo acquisition) positioning for future growth

Risks management surfaced:

Lighter than normal Q1 respiratory season at CepheidGlobal environment becoming more dynamic with ongoing Middle East conflictPotential pressures from sustained regional conflict despite limited direct exposureContinued volume-based procurement and reimbursement policy changes in ChinaNorth America academic research customer funding constraints

Q&A highlights

Michael Riskin · Bank of America

Analyst asked about progression of core growth through 2026, specifically questioning the implied acceleration from Q1's 0.5% to ~2% in Q2 and higher in H2, and what's driving the ramp across segments given China diagnostics and respiratory headwinds.

Management confirmed three expected drivers are playing out: (1) China diagnostics policy headwinds as expected with higher patient volumes; (2) diagnostics excluding China/respiratory showing mid-single-digit growth with Cepheid gaining share; (3) bioprocessing showing strong consumables and 30%+ equipment order growth. Collective headwinds of ~300 basis points in H1 expected to abate by year-end, supporting mid-single-digit full-year guidance without assuming end-market improvement.

Q1 core growth 0.5%Low single-digit core growth guidance for H1 2026Mid-single-digit core growth guidance for full year 2026Diagnostics ex-China/respiratory: mid-single-digit growth

Vijay Kumar · Evercore ISI

Analyst questioned the strategic rationale for Massimo acquisition, noting initial market confusion about why a life sciences company was acquiring a MedTech asset, and sought details on call-point synergies and expected ROIC.

Management described Massimo as consistent with Danaher's three-dimensional acquisition framework: mission-critical, differentiated technology in attractive end market with secular growth. Direct synergies outlined as $125M cost synergies by year five ($50M gross margin, $50M OPEC, $25M public company costs) and $50M revenue synergies. Geographic complementarity with Radiometer (Massimo stronger in US, Radiometer in Europe). Financial profile accretive to growth, gross margin, and operating margin with high single-digit year-five ROIC target.

Massimo acquisition: $125M cost synergies by year fiveCost synergies breakdown: $50M gross margin, $50M OPEC, $25M public company costsRevenue synergies: ~$50MTarget ROIC: high single-digit in year five

Jack Meehan · Nephron Research

Analyst asked how AI is influencing customer spending behavior across business segments (bioprocessing, life sciences, diagnostics) and whether management is seeing tangible signs of productivity benefits from AI-enabled DBS.

Management positioned AI as a growth accelerator for pharma/biotech through improved drug development pipeline yields (currently ~10%). Short-term demand drivers include autonomous science and biologic models requiring automation, analytical instruments, and reagents. Long-term benefits include compressed cycle times and increased hit rates. DBS and AI now synonymous in driving efficiencies, resulting in more/better AI-enabled products and lower costs. No specific productivity metrics or cost savings targets quantified.

Current drug development pipeline yield: ~10%Autonomous science positioned as near-term growth driverBiologic models require significantly more information than large language modelsAI positioned as multi-year growth driver across discovery, development, and manufacturing

Tycho Peterson · Jefferies

Analyst requested unpacking of bioprocessing dynamics by customer type (pharma vs biotech vs CDMOs), replacement cycle demand, and sizing of China biotech opportunity (previously $1.3B at peak).

Management noted China bioprocessing grew double-digit in Q1 driven by biotech accelerating. Monetization of therapies resolving through license deals and restored IPO/stock exchange activity. Indicated $1.3B prior peak may take time but on path to improvement; encouraged by funnel activity and equipment order growth supporting 2026+ hypothesis. Expects positive progression through 2026 with upside potential beyond. Did not provide updated sizing for China biotech opportunity.

China bioprocessing: double-digit growth in Q1 2026China biologics driven by biotech market accelerationPrior peak China biotech opportunity: $1.3BFunnel activity and equipment orders supporting 2026+ growth

Casey Woodring · JP Morgan

Analyst questioned whether >30% bioprocessing equipment order growth is off a light comparable base and requested sequentials/book-to-bill data. Also asked about brownfield vs greenfield investment dynamics and timing of greenfield orders.

Management confirmed Q1 2026 was first positive year-over-year orders growth in ~2 years (lighter comp acknowledged). Q1 orders down sequentially due to normal seasonality. Funnel activity robust. Orders driven by two vectors: (1) underinvestment over past 2 years despite strong consumables growth requiring capacity expansion for biosimilars/new compounds, and (2) reshoring dynamic with brownfield and potential greenfield orders. No specific sequentials or book-to-bill ratios provided. Indicated greenfield orders would follow brownfield; no specific timing given for H2 2026.

Q1 2026 bioprocessing equipment orders: first positive YoY growth in ~2 yearsQ1 sequential orders: down as expected due to seasonalityBioprocessing consumables: robust, multi-year strong growthCapacity expansion drivers: biosimilars, new compounds, underinvestment, reshoring

Answers to last quarter's watch list

Equipment order conversion — Bioprocessing equipment orders grew >30% YoY in Q1, the first positive YoY print in nearly two years, and management upgraded the framing to "early stages of a multi-year investment cycle." That said, sequential orders were down on seasonality and book-to-bill was not disclosed despite a direct request. Order growth is real; conversion timing to revenue remains unclear.

Resolved positively

Life sciences consumables stabilization at IDT/Aldevron/AppCamp — Life Sciences core grew +0.5%, and management cited "early signs of momentum building in our order book" at academic customers. No customer-specific update on the previously named two large plasmid/mRNA customers. Direction better, magnitude unconvincing.

Continue monitoring

FY2025 EPS landing within or above $7.70–$7.80 — Not addressed in the Q1 FY26 release; FY25 closed prior to this print and FY26 EPS now guided $8.35–$8.55, implying ~9–10% growth off the prior FY base, consistent with the prior framing.

Resolved positively

Cepheid respiratory tracking toward $1.7B FY2026 endemic rate — Materially weaker than expected. FY26 guide was quietly narrowed from "approximately $1.7B" to "$1.6–$1.7B," with Q1 called out as "lighter than normal respiratory season." Endemic baseline is being walked down by ~$0.05B at the midpoint.

Resolved negatively

China VBP headwind sizing for 2026 — VBP pricing pressure came in as expected, with management noting volumes were slightly better than anticipated. No updated dollar sizing of the FY26 headwind. Pressure on track; volume offset providing modest cushion.

Continue monitoring

Margin upside vs. >100bps 2026 commitment — Q1 adj. operating margin came in at 30.2% (+60bps YoY); Q2 is guided ~26.5%, a seasonal step-down driven by respiratory seasonality, FX, and pulled-forward growth investments rather than underlying margin compression. No upward revision to the >100bps FY frame despite the EPS high-end nudge.

Continue monitoring

What to watch into next quarter

Q2 core growth landing at the high end of low-single-digit (~3%) versus the low end (~1%) — Q1 came in at 0.5% against a low-single-digit guide; another print near the low end of the Q2 guide makes the FY 3–6% range arithmetically very hard to hit and forces a guidance reset on the Q2 call.

Bioprocessing equipment order conversion to revenue — orders +30% YoY is the inflection signal; watch whether revenue from those orders begins appearing in Biotechnology equipment lines by Q3 FY26, and whether the +30% rate sustains or was comp-aided.

Cepheid respiratory endemic rate trajectory — the silent narrowing of FY26 respiratory to $1.6–$1.7B sets up Q2 (off-season) as a clean read on baseline; any further trim opens the question of whether $1.6B is the floor or just the next stop.

Book-to-bill disclosure — management declined to provide the metric this quarter; if it doesn't return on the Q2 call as orders inflect, that is itself a signal worth weighting.

Masimo deal close timing and FY26 contribution disclosure — accretion in Year 1 is committed; watch for revised FY26 EPS guide with-and-without Masimo once close timing firms up, and whether the high-single-digit Year 5 ROIC target draws pushback.

Implied H2 core revenue ramp — to hit the 3% FY low end, H2 needs roughly mid-single-digit core growth; watch for any incremental disclosure on H2 visibility (funnel-to-order conversion data, pharma capex commentary) versus reliance on headwind abatement alone.

Sources

Danaher Q1 FY2026 Press Release (SEC EDGAR), 2026-04-21: https://www.sec.gov/Archives/edgar/data/313616/000031361626000109/dhr-20260421xex991.htm
Danaher Q1 FY2026 earnings call Q&A (referenced via extraction)
Tapebrief Q3 FY2025 and Q2 FY2025 prior-coverage briefs

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.